ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The ...

ImmunityBio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that SpaceX investors ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of ...

IBRX’s current market capitalization is around $9 billion, positioning the stock as a candidate for inclusion in the large-cap index. ・Potential addition to the Russell 1000 could attract passive ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

ImmunityBio’s (IBRX) meteoric rise this year has forced short sellers betting against the cancer drug developer to record roughly $492M in paper losses in the first 12 trading days of 2026, Bloomberg ...

View ImmunityBio Inc IBRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study. ImmunityBio said the QUILT 3.055 trial shows median ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine ...

Currently, ImmunityBio's flagship Anktiva drug is approved to treat patients with bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) who have Carcinoma in Situ (CIS ...